Drug Topics June 11, 2024
Killian Meara

The Lingo and Libre Rio from Abbott are based on the company’s FreeStyle Libre sensing technology.

The FDA has provided clearance to 2 over-the-counter (OTC) continuous glucose monitor (CGM) systems, health care technology company Abbott announced in a release.1 The new OTC devices are based on the company’s FreeStyle Libre sensing technology, which is the most widely used CGM system in the world.

The Lingo and Libre Rio were both designed to meet different consumer needs. The Lingo aims to help adults gain a better understanding of their health and improve wellness, while the Libre Rio is for adults with type 2 diabetes (T2D) who do not use insulin and typically manage their disease through lifestyle modifications. The approval for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, FDA, Govt Agencies, Medical Devices, Technology, Wearables
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article